Intellia Therapeutics March 02, 2026 -- Intellia Therapeutics, Inc. (NTLA), announced that the U.S. FDA has removed the clinical hold on the Investigational New Drug application (IND) for the MAGNITUDE Phase 3 clinical trial of nexiguran ziclumeran (nex-z) for patients with transthyretin amyloidosis with cardiomyopathy. From Intellia Therapeutics Intellia President and Chief Executive Officer John Leonard, M . . . This content is for paid …
Intellia Therapeutics in the NEWS February 26, 2026, Intellia Therapeutics, Inc. (NTLA), reported business updates and financial results for the fourth quarter and year ended December 31, 2025. From Intellia Therapeutics Intellia President and Chief Executive Officer John Leonard, M.D, said, “2025 was a time of accomplishment and resiliency for Intellia . . . This content is for paid subscribers. Please click here to subscribe or here to log …
Novo Nordisk in the NEWS February 24, 2026 – Novo Nordisk (NVO) announced that, effective January 1, 2027, the company will lower the list price, or wholesale acquisition cost (WAC), of Wegovy® (semaglutide) injection 2.4 mg and tablets 25 mg, Ozempic® (semaglutide) injection 0.5 mg, 1 mg, and . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
Merck - Human Health Business RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (MRK) - known as MSD outside of the United States and Canada, today highlighted steps to evolve the structure of its Human Health organization to ensure strong commercial execution of launches across diverse therapeutic areas, positioning the company for continued commercial success. As part of this evolution, Merck is organizing its . . . This content …
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., February 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NTLA) - a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, announced that on February 1, 2026, it awarded inducement grants to six new employees under Intellia’s 2024 Inducement Plan as a material inducement . . . This content is for …
Intellia Therapeutics News January 27, 2026, Intellia Therapeutics, Inc. (NTLA), today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on the Investigational New Drug application (IND) for the MAGNITUDE-2 Phase 3 clinical trial of nexiguran ziclumeran (nex-z) for patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv . . . This content is for paid subscribers. Please click here to subscribe …
BioCryst Pharmaceuticals Acquires Astria Pharmaceuticals Today, January 23, 2026, BioCryst Pharmaceuticals, Inc. (BCRX) announced it completed acquisition of Astria Therapeutics, Inc., initially announced on October 14, 2025. The transaction strengthens its position as a leader in hereditary angioedema (HAE) and enhances the company’s long-term growth trajectory. BioCryst adds navenibart BioCryst, a late-stage, long . . . This content is for paid subscribers. Please click here to …
Eli Lilly The FDA extended its review for Eli Lilly (LLY) oral obesity drug, orforglipron, pushing the target decision date to April 10, 2026, from earlier expectations of late March, despite it receiving a Commissioner's National Priority Voucher for faster . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
Anavex Life Sciences Corp Today, January 13, 2026, Anavex Life Sciences Corp. (AVXL) announced its participation as a key industry partner in ACCESS-AD, a major new European initiative designed to accelerate the adoption of innovative diagnostic and therapeutic approaches for Alzheimer’s disease (AD) across real‑world clinical settings. The multi-year program is funded by the . . . This content is for paid subscribers. Please click here …
AbbVie and RemeGen Announce Licensing Agreement Today, January 12, 2026, - AbbVie (ABBV) and RemeGen announced an exclusive licensing agreement for the development, manufacturing and commercialization of RC148, a novel investigational Programmed Cell Death-1 (PD-1)/Vascular Endothelial Growth Factor (VEGF)-targeted bispecific antibody. RC148 is currently being developed by RemeGen as a monotherapy . . . This content is for paid subscribers. Please click here to subscribe or …
Insmed Inc Insmed Inc is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. Insmed is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's most advanced programs are in pulmonary and inflammatory …
Rapport Therapeutics in the NEWS Today, January 07, 2026, Rapport Therapeutics, Inc. (RAPP) announced plans to initiate its Phase 3 program for RAP-219 in FOS in the second quarter of 2026 and expand its epilepsy portfolio with a new program in PGTCS. Additionally, the Company announced progress across its pipeline, including . . . This content is for paid subscribers. Please click here to subscribe or …
Novo Nordisk PLAINSBORO, N.J. and BAGSVÆRD, Denmark, Dec. 18, 2025 /PRNewswire/ -- Today, Novo Nordisk (NVO) announced the submission of a New Drug Application (NDA) to the U.S. FDA for once-weekly CagriSema (cagrilintide 2.4 mg and semaglutide 2.4 mg) injection, to be used with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain . . . This content is for paid subscribers. Please click here to …
Immunome Inc Immunome, Inc. (IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today the firm announced positive topline results from the global pivotal Phase 3 RINGSIDE trial of varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), in patients with progressing desmoid tumors. The trial met its primary . . . This content is for paid subscribers. Please click here to …
Rhythm Pharmaceuticals Today, Rhythm Pharmaceuticals, Inc. (RYTM), announced positive preliminary results from its exploratory Phase 2 trial of setmelanotide in patients with Prader-Willi syndrome (PWS). The firm also announced plans to advance setmelanotide into a Phase 3 registrational trial in PWS, pending successful completion of . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
Cidara Therapeutics Q3 Financial Results SAN DIEGO, November 06, 2025, Cidara Therapeutics, Inc. (CDTX) reported financial results for the third quarter ended September 30, 2025, and provided recent business updates. From Cidara Therapeutics Jeffrey Stein, Ph.D., president and chief executive officer of Cidara, said, “With our Phase 3 ANCHOR study now over 50 percent enrolled, we expect to achieve target enrollment . . . This …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
